% | $
Quotes you view appear here for quick access.

Seattle Genetics, Inc. Message Board

you are viewing a single comment's thread.

view the rest of the posts
  • slumdawg2011 slumdawg2011 Nov 11, 2012 7:38 PM Flag


    The superiority of enzalutamide over placebo was shown with respect to all secondary end points: the proportion of patients with a reduction in the prostate-specific antigen (PSA) level by 50% or more (54% vs. 2%, P

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • And finally:
      From ph1/2 of enzalutamide, 37% had CTC conversion from favorable to unfavorable.
      For JnJs abiraterone ph3, 34-41% had CTC conversion from favorable to unfavorable, while 36-51% had psa decline 50% at week 12.

      Based on placebo arm of enzalutamide ph3, it does look like PGNX's anti-PSMA ADC is demonstrating activity. It would be good to see the tables presented in the EORTC conference.

50.36-0.47(-0.92%)Oct 24 4:00 PMEDT